Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Epidemiological data on postprandial glycaemia.

B Balkau1, E Eschwège

  • 1balkau@vjf.inserm.fr

Diabetes & Metabolism
|March 22, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increased risk of type 2 diabetes in antidepressant users: evidence from a 6-year longitudinal study in the E3N cohort.

Diabetic medicine : a journal of the British Diabetic Association·2020
Same author

Learning about diabetes through epidemiology.

Diabetic medicine : a journal of the British Diabetic Association·2020
Same author

Dairy consumption is associated with lower plasma dihydroceramides in women from the D.E.S.I.R. cohort.

Diabetes & metabolism·2019
Same author

Associations between sleep duration and sleep debt with insulin sensitivity and insulin secretion in the EGIR-RISC Study.

Diabetes & metabolism·2018
Same author

Determinants of 20-year non-progression to Type 2 diabetes in women at very high risk: the E3N cohort study.

Diabetic medicine : a journal of the British Diabetic Association·2018
Same author

Haemoglobin A1c and 5-year all-cause mortality in French type 2 diabetic patients aged 70 years and older: The GERODIAB observational cohort.

Diabetes & metabolism·2018
Same journal

Glucagon-like peptide-1 receptor agonists and risk of pancreaticobiliary cancers in patients with type 2 diabetes: a nationwide cohort study.

Diabetes & metabolism·2026
Same journal

Decreased risk of new-onset osteoporosis in patients with Type 2 diabetes on SGLT-2 inhibitors.

Diabetes & metabolism·2026
Same journal

Two faces of autoimmune hyperinsulinemia: contrasting type B insulin resistance syndrome and exogenous insulin antibody syndrome.

Diabetes & metabolism·2026
Same journal

CGM-based metrics and mortality in older adults living with type 2 diabetes on insulin therapy: a secondary analysis of the HYPOAGE study.

Diabetes & metabolism·2026
Same journal

Persistent burden and management gaps of hypoglycemia in pediatric type 1 diabetes: insights from the Epi-GLUREDIA Study.

Diabetes & metabolism·2026
Same journal

Blood oxygen saturation and its associations with autonomic and peripheral neuropathy in diabetes.

Diabetes & metabolism·2026
See all related articles

Postprandial hyperglycemia, or high blood sugar after meals, may impact cardiovascular health differently than fasting glucose. More research is needed to confirm if treatments targeting postprandial glucose, like acarbose, reduce cardiovascular disease risks in diabetics.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Cardiovascular Research

Background:

  • Postprandial hyperglycemia is often assumed to have similar effects as post-glucose-load hyperglycemia.
  • Epidemiological data suggests 2-hour post-load glucose predicts cardiovascular mortality, while both fasting and 2-hour glucose predict retinopathy.
  • Clinical trials lowering glucose in type 2 diabetes have shown mixed results for cardiovascular disease, contrasting with micro-vascular benefits.

Purpose of the Study:

  • To investigate the distinct effects of postprandial hyperglycemia compared to post-glucose-load hyperglycemia.
  • To evaluate the role of postprandial glucose control in cardiovascular outcomes.
  • To assess the potential of glucose-lowering agents like acarbose in cardiovascular disease prevention.

Main Methods:

Related Experiment Videos

  • Comparison of glucose concentrations from tests involving a standardized "diabetes screening product" versus a 75 g oral glucose load.
  • Review of epidemiological evidence linking glucose levels to cardiovascular mortality and retinopathy.
  • Analysis of clinical trial data, including the STOP-NIDDM trial, examining glucose-lowering agents and cardiovascular outcomes.

Main Results:

  • Glucose concentrations during postprandial and post-glucose-load tests show high correlation.
  • While hyperglycemia links to cardiovascular mortality, glucose-lowering interventions in type 2 diabetes have not consistently reduced cardiovascular disease rates.
  • The STOP-NIDDM trial indicated a potential cardiovascular benefit from acarbose, a postprandial glucose-lowering drug, though further studies are required due to small event numbers.

Conclusions:

  • Confirmatory studies are necessary to establish the efficacy of acarbose in cardiovascular prevention and to attribute benefits specifically to postprandial glucose treatment.
  • The relationship between postprandial hyperglycemia and cardiovascular disease requires further elucidation.
  • Other co-existing cardiovascular risk factors in diabetic patients may contribute to cardiovascular disease independently of glucose control.